Last reviewed · How we verify
DEFINITY
Definity works by being taken up by cells in the body, where it is metabolized and eventually eliminated.
Definity is a small molecule modality developed by Lantheus Medical Imaging, but its target, drug class, and approved indications are unknown. As a commercial product, its status is patented, and it is owned by Lantheus Medical Imaging. The safety considerations of Definity are not publicly available. Further information on its pharmacological properties, such as half-life and bioavailability, is also lacking. As a result, its use and potential side effects are not well understood.
At a glance
| Generic name | DEFINITY |
|---|---|
| Also known as | DEFINITY, Perflutren Lipid Microsphere injectable suspension, Perflutren Lipid Microsphere, ultrasound contrast agent or microbubbles, Perflutren |
| Sponsor | Lantheus Medical Imaging |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Mechanism of action
Imagine Definity as a small molecule that gets absorbed into the body's cells, where it's broken down and removed over time. This process is similar to how the body naturally processes and eliminates other substances. However, the exact details of how Definity interacts with the body's cells and systems are not well understood.
Approved indications
Boxed warnings
- WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration. Assess all patients for the presence of any condition that precludes DEFINITY RT administration [see Contraindications (4) ] . Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)
Common side effects
- Headache
- Back/Renal Pain
- Flushing
- Nausea
- Chest Pain
- Injection Site Reactions
- Dizziness
- Fatigue
- Fever
- Hot Flushes
- Pain
- Rigors
Serious adverse events
- Serious Cardiopulmonary Adverse Reactions
- Fatal Cardiac or Respiratory Arrest
- Anaphylaxis
- Shock
- Ventricular Fibrillation
- Ventricular Tachycardia
- Bronchospasm
- Angioedema
- Symptomatic Arrhythmias
- Dyspnea
Key clinical trials
- Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer (PHASE1)
- Influence of Tamponade on Retinal Shift in Eyes Undergoing Vitrectomy for Rhegmatogenous Retinal Detachment: A Comparison of Gas Versus Silicone Oil in a Pakistani Population (NA)
- Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant Radiotherapy (EARLY_PHASE1)
- SONOthrombolysis in Patients With an ST-segment Elevation Myocardial Infarction With fibrinoLYSIS (SONOSTEMI-LYSIS) Trial (PHASE2)
- Xenon-129 and Inert Fluorinated Gas Lung MRI: Study of Healthy Volunteers and Participants With Pulmonary Disease (PHASE2)
- Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma (NA)
- Prediction of Neoadjuvant Chemotherapy Response Using Contrast-Enhanced Ultrasound in Patients With Locally Advanced Breast Cancer (PHASE2,PHASE3)
- 19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DEFINITY CI brief — competitive landscape report
- DEFINITY updates RSS · CI watch RSS
- Lantheus Medical Imaging portfolio CI